LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

Siemens Healthineers Hemoglobin A1c Test Now Available on Atellica Solution

By LabMedica International staff writers
Posted on 18 May 2019
Print article
Image: The Atellica CH Enzymatic Hemoglobin A1c (A1c_E) Assay (Photo courtesy of Siemens Healthineers).
Image: The Atellica CH Enzymatic Hemoglobin A1c (A1c_E) Assay (Photo courtesy of Siemens Healthineers).
The Atellica CH Enzymatic Hemoglobin A1c (A1c_E) Assay is an easy-to-implement chemistry test, offering precise and accurate results for diabetic patient management.

The A1c_E assay is less prone to testing interference and greatly improves laboratory throughput compared to traditional HPLC assays.

Siemens Healthineers (Tarrytown, NY, USA) has announced the global availability of its new Atellica CH Enzymatic Hemoglobin A1c (A1c_E) Assay to assist clinicians in diagnosing and monitoring diabetes, a growing and potentially deadly disease.

The International Diabetes Federation projects 642 million people worldwide will have diabetes by 2040 because of leading factors such as higher levels of urbanization, aging populations, and the growing adoption of more sedentary lifestyles which leads to insufficient physical activity, greater rates of obesity and a higher intake of unhealthy foods. When diagnosed, treated and monitored regularly, diabetes is manageable and, in some cases, reversible. Left untreated, however, blood sugar can rise to dangerous levels and lead to kidney damage and other irreversible health consequences.

As diabetes awareness increases and screening for the chronic disease rises, testing options for the clinical laboratory are evolving both in sophistication and practicality. The Siemens Healthineers Atellica CH Enzymatic Hemoglobin A1c meets new standards of testing and offers laboratories improved performance - both precision and accuracy - over leading alternative methodologies.

Siemens Healthineers offers a variety of HbA1c assays for diabetes testing on its clinical laboratory and point-of-care solutions, including the Atellica CH Analyzer, ADVIA Chemistry Systems, Dimension Systems, Dimension Vista Systems, and the DCA Vantage Analyzer.

“Demands for screening and monitoring on the laboratory will continue to grow as the diabetic population continues to expand,” said Dr. Deepak Nath, president of laboratory diagnostics at Siemens Healthineers. “Instruments with higher throughput capabilities offer laboratories the ability to run a greater volume of tests and produce patient results more quickly, thus improving patient satisfaction. Laboratories are seeking HbA1c assays that can be integrated onto chemistry testing platforms and that provide the accurate and precise results patients deserve. The new Atellica CH Enzymatic Hemoglobin A1c Assay offers these capabilities.”

Platinum Member
COVID-19 Rapid Test
OSOM COVID-19 Antigen Rapid Test
Magnetic Bead Separation Modules
MAG and HEATMAG
Anti-Cyclic Citrullinated Peptide Test
GPP-100 Anti-CCP Kit
New
Gold Member
TORCH Panel Rapid Test
Rapid TORCH Panel Test

Print article

Channels

Clinical Chemistry

view channel
Image: The 3D printed miniature ionizer is a key component of a mass spectrometer (Photo courtesy of MIT)

3D Printed Point-Of-Care Mass Spectrometer Outperforms State-Of-The-Art Models

Mass spectrometry is a precise technique for identifying the chemical components of a sample and has significant potential for monitoring chronic illness health states, such as measuring hormone levels... Read more

Hematology

view channel
Image: The CAPILLARYS 3 DBS devices have received U.S. FDA 510(k) clearance (Photo courtesy of Sebia)

Next Generation Instrument Screens for Hemoglobin Disorders in Newborns

Hemoglobinopathies, the most widespread inherited conditions globally, affect about 7% of the population as carriers, with 2.7% of newborns being born with these conditions. The spectrum of clinical manifestations... Read more

Immunology

view channel
Image: The AI predictive model identifies the most potent cancer killing immune cells for use in immunotherapies (Photo courtesy of Shutterstock)

AI Predicts Tumor-Killing Cells with High Accuracy

Cellular immunotherapy involves extracting immune cells from a patient's tumor, potentially enhancing their cancer-fighting capabilities through engineering, and then expanding and reintroducing them into the body.... Read more

Microbiology

view channel
Image: The T-SPOT.TB test is now paired with the Auto-Pure 2400 liquid handling platform for accurate TB testing (Photo courtesy of Shutterstock)

Integrated Solution Ushers New Era of Automated Tuberculosis Testing

Tuberculosis (TB) is responsible for 1.3 million deaths every year, positioning it as one of the top killers globally due to a single infectious agent. In 2022, around 10.6 million people were diagnosed... Read more